Logo image of HSCS

HEARTSCIENCES INC (HSCS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:HSCS - US42254E3027 - Common Stock

2.67 USD
-0.14 (-4.98%)
Last: 11/26/2025, 4:30:01 PM
Fundamental Rating

2

Taking everything into account, HSCS scores 2 out of 10 in our fundamental rating. HSCS was compared to 188 industry peers in the Health Care Equipment & Supplies industry. HSCS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. HSCS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

HSCS had negative earnings in the past year.
HSCS had a negative operating cash flow in the past year.
In the past 5 years HSCS always reported negative net income.
In the past 5 years HSCS always reported negative operating cash flow.
HSCS Yearly Net Income VS EBIT VS OCF VS FCFHSCS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 -2M -4M -6M -8M

1.2 Ratios

HSCS has a worse Return On Assets (-136.22%) than 83.51% of its industry peers.
The Return On Equity of HSCS (-279.15%) is worse than 75.53% of its industry peers.
Industry RankSector Rank
ROA -136.22%
ROE -279.15%
ROIC N/A
ROA(3y)-156.79%
ROA(5y)-165.73%
ROE(3y)-2372.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HSCS Yearly ROA, ROE, ROICHSCS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K

1.3 Margins

HSCS has a Gross Margin (57.14%) which is comparable to the rest of the industry.
HSCS's Gross Margin has improved in the last couple of years.
HSCS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 57.14%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.97%
GM growth 5Y15.56%
HSCS Yearly Profit, Operating, Gross MarginsHSCS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025 0 -50K -100K -150K

5

2. Health

2.1 Basic Checks

HSCS does not have a ROIC to compare to the WACC, probably because it is not profitable.
HSCS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, HSCS has less shares outstanding
Compared to 1 year ago, HSCS has a worse debt to assets ratio.
HSCS Yearly Shares OutstandingHSCS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
HSCS Yearly Total Debt VS Total AssetsHSCS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M

2.2 Solvency

Based on the Altman-Z score of -19.35, we must say that HSCS is in the distress zone and has some risk of bankruptcy.
HSCS's Altman-Z score of -19.35 is on the low side compared to the rest of the industry. HSCS is outperformed by 87.23% of its industry peers.
There is no outstanding debt for HSCS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -19.35
ROIC/WACCN/A
WACC7.91%
HSCS Yearly LT Debt VS Equity VS FCFHSCS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 5M -5M

2.3 Liquidity

HSCS has a Current Ratio of 1.47. This is a normal value and indicates that HSCS is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of HSCS (1.47) is worse than 77.13% of its industry peers.
HSCS has a Quick Ratio of 1.25. This is a normal value and indicates that HSCS is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of HSCS (1.25) is worse than 66.49% of its industry peers.
Industry RankSector Rank
Current Ratio 1.47
Quick Ratio 1.25
HSCS Yearly Current Assets VS Current LiabilitesHSCS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 2M 4M 6M

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 79.48% over the past year.
The Revenue for HSCS has decreased by -76.34% in the past year. This is quite bad
The Revenue for HSCS have been decreasing by -41.50% on average. This is quite bad
EPS 1Y (TTM)79.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.15%
Revenue 1Y (TTM)-76.34%
Revenue growth 3Y-32.65%
Revenue growth 5Y-41.5%
Sales Q2Q%N/A

3.2 Future

HSCS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.73% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y30.91%
EPS Next 2Y22.73%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HSCS Yearly Revenue VS EstimatesHSCS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2027 500K 1M 1.5M
HSCS Yearly EPS VS EstimatesHSCS Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -20 -40 -60

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HSCS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HSCS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HSCS Price Earnings VS Forward Price EarningsHSCS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HSCS Per share dataHSCS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

A more expensive valuation may be justified as HSCS's earnings are expected to grow with 22.73% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.73%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

HSCS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

HEARTSCIENCES INC

NASDAQ:HSCS (11/26/2025, 4:30:01 PM)

2.67

-0.14 (-4.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)09-11 2025-09-11/amc
Earnings (Next)12-11 2025-12-11
Inst Owners2.33%
Inst Owner Change190.66%
Ins Owners1.67%
Ins Owner Change-16.78%
Market Cap8.20M
Revenue(TTM)6.30K
Net Income(TTM)-8.77M
Analysts82.5
Price Target13.77 (415.73%)
Short Float %0.69%
Short Ratio0.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.28%
Min EPS beat(2)18.08%
Max EPS beat(2)18.47%
EPS beat(4)3
Avg EPS beat(4)9.66%
Min EPS beat(4)-6.31%
Max EPS beat(4)18.47%
EPS beat(8)4
Avg EPS beat(8)-46.62%
EPS beat(12)7
Avg EPS beat(12)-29.34%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-7.92%
EPS NY rev (1m)0%
EPS NY rev (3m)16.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1301.1
P/FCF N/A
P/OCF N/A
P/B 2.61
P/tB 5.38
EV/EBITDA N/A
EPS(TTM)-8.3
EYN/A
EPS(NY)-4.62
Fwd EYN/A
FCF(TTM)-2.4
FCFYN/A
OCF(TTM)-2.39
OCFYN/A
SpS0
BVpS1.02
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -136.22%
ROE -279.15%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 57.14%
FCFM N/A
ROA(3y)-156.79%
ROA(5y)-165.73%
ROE(3y)-2372.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.97%
GM growth 5Y15.56%
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 92.07%
Cap/Sales 479.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.47
Quick Ratio 1.25
Altman-Z -19.35
F-Score2
WACC7.91%
ROIC/WACCN/A
Cap/Depr(3y)199.15%
Cap/Depr(5y)121.34%
Cap/Sales(3y)570.65%
Cap/Sales(5y)345.57%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)79.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40.15%
EPS Next Y30.91%
EPS Next 2Y22.73%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-76.34%
Revenue growth 3Y-32.65%
Revenue growth 5Y-41.5%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-32.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2.51%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-37.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-36.93%
OCF growth 3YN/A
OCF growth 5YN/A

HEARTSCIENCES INC / HSCS FAQ

What is the fundamental rating for HSCS stock?

ChartMill assigns a fundamental rating of 2 / 10 to HSCS.


What is the valuation status of HEARTSCIENCES INC (HSCS) stock?

ChartMill assigns a valuation rating of 1 / 10 to HEARTSCIENCES INC (HSCS). This can be considered as Overvalued.


What is the profitability of HSCS stock?

HEARTSCIENCES INC (HSCS) has a profitability rating of 1 / 10.


How financially healthy is HEARTSCIENCES INC?

The financial health rating of HEARTSCIENCES INC (HSCS) is 5 / 10.